Ondansetrom Labesfal (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Labesfal, is a 5-HT3 receptor antagonist presented as an intravenous solution for injection for intravenous use. It prevents and treats nausea and vomiting caused by chemotherapy and surgery in adult and pediatric patients. GNH USA supplies Ondansetrom Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron acts on the serotonin pathway to control emesis in several clinical settings. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. - Radiation therapy‑induced nausea and vomiting: helps control nausea and vomiting associated with radiotherapy.

Common Side Effects: - Headache: mild to moderate pain often reported after administration. - Constipation: reduced bowel movements may occur. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - QT prolongation: may lead to cardiac arrhythmias. - Severe allergic reactions (anaphylaxis): rare but potentially life‑threatening. - Serotonin syndrome: risk when combined with other serotonergic agents.

Before initiating therapy, consider the following precautions: - Assess cardiac risk: obtain baseline ECG to evaluate QT interval. - Monitor electrolytes: correct hypokalemia or hypomagnesemia which can exacerbate QT prolongation. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant use with other QT‑prolonging drugs: increased risk of arrhythmia. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Major Interactions (Avoid): - Other QT‑prolonging drugs: may increase risk of serious cardiac arrhythmias. - Apomorphine: can cause severe hypotension when combined. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce ondansetron effectiveness. - Anticholinergic agents: may diminish antiemetic efficacy.